ストックスクリーナーアプリを入手
7.27
0.55%
-0.04
前日終値:
$7.31
開ける：
$7.33
24時間の取引高:
586.56K
Relative Volume:
0.63
時価総額：
$4.94B
収益：
$7.57B
当期純損益:
$216.85M
株価収益率:
22.90
EPS:
0.3174
ネットキャッシュフロー:
$709.16M
1週間 パフォーマンス:
-6.68%
1か月 パフォーマンス:
-12.20%
6か月 パフォーマンス:
-18.77%
1年 パフォーマンス:
+8.83%
1日の値動き範囲:
$7.19
$7.33
1週間の範囲:
$7.13
$7.81
52週間の値動き範囲:
$5.79
$9.96
Grifols Sa Adr Stock (GRFS) Company Profile
GRFS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GRFS
Grifols Sa Adr
|
7.27 | 4.94B | 7.57B | 216.85M | 709.16M | 0.3174 |
|
LLY
Lilly Eli Co
|
822.51 | 738.75B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
205.29 | 363.15B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
163.71 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
69.30 | 311.44B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
89.23 | 225.40B | 64.17B | 17.12B | 18.10B | 6.73 |
Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-12 | 再開されました | Morgan Stanley | Overweight |
| 2024-03-12 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-04-12 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-03 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-16 | アップグレード | Barclays | Underweight → Equal Weight |
| 2023-01-18 | アップグレード | Jefferies | Hold → Buy |
| 2022-04-08 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-11-05 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2021-10-19 | ダウングレード | Barclays | Overweight → Underweight |
| 2021-10-06 | アップグレード | Citigroup | Neutral → Buy |
| 2021-06-14 | アップグレード | Deutsche Bank | Hold → Buy |
| 2021-04-20 | 開始されました | Deutsche Bank | Hold |
| 2021-03-23 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-03-11 | アップグレード | HSBC Securities | Hold → Buy |
| 2020-10-01 | アップグレード | Citigroup | Sell → Neutral |
| 2020-06-09 | ダウングレード | Citigroup | Neutral → Sell |
| 2020-06-09 | アップグレード | HSBC Securities | Reduce → Hold |
| 2020-03-25 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-06-27 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-02-08 | ダウングレード | Berenberg | Buy → Hold |
| 2018-10-11 | アップグレード | Berenberg | Hold → Buy |
| 2018-06-01 | 開始されました | Barclays | Overweight |
| 2017-10-31 | 開始されました | Citigroup | Buy |
| 2017-06-30 | ダウングレード | Goldman | Buy → Neutral |
| 2017-04-06 | 開始されました | BofA/Merrill | Buy |
| 2017-01-03 | アップグレード | JP Morgan | Neutral → Overweight |
| 2016-02-09 | アップグレード | Berenberg | Hold → Buy |
| 2016-01-04 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2015-12-02 | ダウングレード | HSBC Securities | Buy → Hold |
| 2015-11-20 | ダウングレード | Berenberg | Buy → Hold |
| 2015-04-28 | ダウングレード | Berenberg | Buy → Hold |
すべてを表示
Grifols Sa Adr (GRFS) 最新ニュース
Deutsche Bank raises Grifols SA price target to EUR11.00 - Investing.com India
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha
Get in on Grifols SA ADR’s (GRFS) buy-in window today! - SETE News
Wall Street analysts’ outlook for Douglas Elliman Inc (DOUG) - SETE News
Financial Metrics Exploration: Understanding Accuray Inc (ARAY) Through Ratios - The Dwinnex
Financial Fitness Check: Examining Mannkind Corp (MNKD)’s Key Ratios - The Dwinnex
Orphan Designated Drugs Market Analysis: Key Trends, Players and Forecasts for Future Growth - GlobeNewswire Inc.
Grifols: More Attractive Than In A Very Long Time (NASDAQ:GRFS) - Seeking Alpha
Grifols Stock Declines After Brookfield Drops Buyout Offer - Barchart
BRF S.A. goes ex dividend tomorrow - MSN
Brookfield Drops $6.8 Billion Offer to Buy Drugmaker Grifols - BNN Bloomberg
Grifols slips as board rebuffs Brookfield’s $6.8B offer (update) - MSN
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - MSN
Grifols falls amid potential Moody's downgrade, new short report - MSN
Grifols stock slips as Brookfield offer rebuffed (GRFS:NASDAQ) - Seeking Alpha
Is it possible to buy Grifols SA ADR(GRFS) shares at a good price now? - US Post News
Grifols SA ADR (GRFS)’s Day in Review: Closing at 8.58, Down by -0.12 - The Dwinnex
RFID Kanban Systems Market Forecast to Reach $9.53 Billion by 2030 - GlobeNewswire Inc.
A Look at Grifols SA ADR (GRFS) Shares in the Recent Past Indicates Growth - SETE News
Cboe Global Markets Inc. (AMEX: CBOE): Getting A Free Pass? - Stocks Register
It is Poised to be a Bull Market for Grifols SA ADR (GRFS) - SETE News
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
Examining Grifols SA ADR (GRFS) stock is warranted - US Post News
Are Grifols SA ADR’shares a good deal? - US Post News
Orange To Delist From NYSE To Reduce Financial Burdens - Yahoo Finance
Ratio Review: Analyzing Grifols SA ADR (GRFS)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Mexico Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
UK Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
Grifols Class B stock falls as Brookfield reportedly seeks lower price - MSN
The UAE Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
Grifols SA ADR (GRFS)’s Market Momentum: Closing Strong at 9.00, Up 2.74 - The Dwinnex
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
Grifols shares up on potential takeover by Brookfield - Investing.com
China Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
India Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
Validea Joseph Piotroski Strategy Daily Upgrade Report8/6/2024 - Nasdaq
Grifols revises past financial records with equity value drop of $494 mln - Marketscreener.com
Grifols: Going Private? Brookfield On The Scene (OTCMKTS:GIFLF) - Seeking Alpha
Grifols, S.A. (BME:GRF) most popular amongst retail investors who own 45% of the shares, institutions hold 35% - Simply Wall St
Grifols shares fall after new Gotham City Research report - Marketscreener.com
Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A.GRFS - PR Newswire
AMBAR, an Encouraging Alzheimer's Trial That Raises Questions - Frontiers
The 10 Most-Bought and Most-Sold European Stocks - Morningstar
Grifols sees China stake sale going ahead despite Gotham City report - Reuters
BreakingviewsShort attack intensifies Grifols’ health problem - Reuters
Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients - PR Newswire UK
Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023 - PR Newswire
Novo Nordisk A/s Dividend History & Dividend Yield 2024 - INDmoney
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson - PR Newswire
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada - PR Newswire
Grifols Sa Adr (GRFS) 財務データ
収益
当期純利益
現金流量
EPS
1.66%
大文字化:
|
ボリューム (24 時間):